Sinopharm Group Co. Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more
Sinopharm Group Co. Ltd (X2S) - Total Assets
Latest total assets as of June 2025: €420.33 Billion EUR
Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) holds total assets worth €420.33 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sinopharm Group Co. Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Sinopharm Group Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sinopharm Group Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinopharm Group Co. Ltd's total assets of €420.33 Billion consist of 88.5% current assets and 11.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.8% |
| Accounts Receivable | €187.64 Billion | 47.8% |
| Inventory | €62.35 Billion | 15.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.72 Billion | 1.2% |
| Goodwill | €6.25 Billion | 1.6% |
Asset Composition Trend (2013–2024)
This chart illustrates how Sinopharm Group Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinopharm Group Co. Ltd's current assets represent 88.5% of total assets in 2024, an increase from 85.1% in 2013.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2024, up from 13.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 6.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 47.8% of total assets.
Sinopharm Group Co. Ltd Competitors by Total Assets
Key competitors of Sinopharm Group Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
Sinopharm Group Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sinopharm Group Co. Ltd generates 1.49x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sinopharm Group Co. Ltd generates $ 1.79 in net profit.
Sinopharm Group Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.34 | 1.35 | 1.27 |
| Quick Ratio | 1.10 | 1.11 | 1.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €95.34 Billion | € 99.12 Billion | € 56.25 Billion |
Sinopharm Group Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Sinopharm Group Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2.5% |
| Total Assets | €392.83 Billion |
| Market Capitalization | $3.18 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sinopharm Group Co. Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sinopharm Group Co. Ltd's assets grew by 2.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sinopharm Group Co. Ltd (2013–2024)
The table below shows the annual total assets of Sinopharm Group Co. Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €392.83 Billion | +2.46% |
| 2023-12-31 | €383.39 Billion | +5.10% |
| 2022-12-31 | €364.78 Billion | +8.75% |
| 2021-12-31 | €335.41 Billion | +7.77% |
| 2020-12-31 | €311.24 Billion | +15.32% |
| 2019-12-31 | €269.89 Billion | +14.47% |
| 2018-12-31 | €235.77 Billion | +39.07% |
| 2017-12-31 | €169.54 Billion | +7.50% |
| 2016-12-31 | €157.71 Billion | +13.11% |
| 2015-12-31 | €139.43 Billion | +8.37% |
| 2014-12-31 | €128.66 Billion | +22.00% |
| 2013-12-31 | €105.45 Billion | -- |